MYC and plasma cell myeloma: Although this is not a fusion protein, it does lead to altered expression levels and is seen in, for example, medulloblastoma (e.g., DDX31–GFI1B), neuroblastoma (e.g., HAND2–MYC), multiple myeloma (e.g., PRDM1–MYC), Burkitt lymphoma (e.g., IG–MYC), embryonal tumor with multilayered rosettes (TTYH1–C19MC) and in the newly identified CNS neuroblastoma tumors with FOXR2 activation (e.g., JMJD1C–FOXR2) [2, 109, 134, 161, 216, 253].